Track topics on Twitter Track topics that are important to you
Conceptus, Inc. has developed Essure, an innovative medical procedure, designed to provide a non-incisional alternative to tubal ligation, the leading form of birth control worldwide. In the United States, Essure is currently an investigational device for non-incisional permanent birth control. The Essure procedure is based on a unique and proprietary micro-insert and catheter delivery system for minimally invasive transcervical tubal access. On April 19, 2002, Conceptus submitted an application to the Food and Drug Administration, seeking approval to market Essure in the United States. The availability of Essure in the U.S. is projected for 2003 and is expected to open up a market currently occupied by surgical tubal ligation and vasectomy, which combined account for more than 1 million sterilization procedures, annually.
The Common Stock of Conceptus has been traded on the Nasdaq National Market under the symbol CPTS since the effective date of the initial public offering on February 1, 1996.
1021 Howard Ave.
United States of America
Phone: 650 802-7240
Fax: 650 610-8363
In vivo delivery of morpholino antisense oligonucleotides (MAO) directly into the uterine lumen of a peri-implantation period pregnant sheep is an effective technique for evaluation of gene products f...
Approximately 65-75 days post-partum (dpp), the estrous cycles of non-lactating (dried off immediately post partum: n = 12) and lactating (n = 13) Holstein Friesian cows were synchronized and on D...
Vitamin D is a secosteroid hormone with many varied functions including regulation of blood calcium levels, cell proliferation, immunity, and reproduction in mammals. Vitamin D is activated by 25-hydr...
Establishment of pregnancy in domestic ruminants includes pregnancy recognition signaling by the conceptus, implantation, and placentation. Despite the high fertilisation success rate in ruminants, a ...
The aim of this study was to test the hypothesis that the metabolic stresses associated with lactation alter the ability of the endometrium to respond appropriately to the conceptus by examining endom...
For implantation of developing conceptus, placental cells need to invade mother's uterus to access maternal blood supply in a control manner. We have found a combination of maternal immun...
In recent artificial frozen embryo transfers (FET) in which blastocysts vitrified on day 4 of culture and transferred on P+4, with blastocysts traditionally transferred on P+5, a high rate...
Conceptus, Inc. (NASDAQ: CPTS), is a leader in the design, development and marketing of innovative solutions in women's healthcare. The Mountain View, Calif.-based company manufac...
Conceptus, Inc. is a leader in the design, development and marketing of innovative solutions in women's healthcare. The Company manufactures and markets Essure permanent birth con...
Conceptus, Inc. has developed Essure, an innovative medical procedure, designed to provide a non-incisional alternative to tubal ligation, the leading form of birth control worldwide. In the United St...
We have published hundreds of Conceptus news stories on BioPortfolio along with dozens of Conceptus Clinical Trials and PubMed Articles about Conceptus for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Conceptus Companies in our database. You can also find out about relevant Conceptus Drugs and Medications on this site too.